Beginning to address an implementation gap in asthma: clinicians' views of prescribing reliever ICS-formoterol inhalers and SMART in the United States.

While new guidelines exist in asthma, many clinicians described significant barriers to utilizing them including medico-legal issues, pharmaceutical formulary confusion, and high drug costs. Nonetheless, most clinicians believed the latest inhaler approaches would be more intuitive for their patients and offer an opportunity for patient-centered collaboration and care. Stakeholders may find these results useful in future attempts to increase the real-world adoption of recent asthma recommendations.